BlossomHill Therapeutics, Inc. — Form 8-K
Filed September 15, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 68/100
What the filing says
BlossomHill Therapeutics reported Phase 1/2 SOLARA trial data for BH-30643, a novel EGFR inhibitor, showing 45% objective response rate (18/40 patients) and 88% disease control rate (35/40) in EGFR C797S-positive NSCLC patients resistant to prior EGFR inhibitors. The drug demonstrated favorable safety with low dose-reduction rates (9%) and discontinuation rates (3%) among 174 patients at expansion doses. BH-30643 recently received FDA Fast Track designation; the company plans to initiate a Phase 2 study in Q1 2027.
Why this rating
Clinical-stage biotech; lead candidate shows encouraging efficacy in unmet-need population with FDA Fast Track backing, advancing toward Phase 2—material for company trajectory but inherent clinical development risk remains.
See more from September 15, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.